Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Foster, James S ^a,b   Fish, Lindsay M ^a,b   Phipps, Jonathan E ^a,b   Bruker, Charles T ^c   Lewis, James M ^a,b   Bell, John L ^a,b   Solomon, Alan ^a,b   Kestler, Daniel P ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^c BOCA RATON REGIONAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ODONTOGENIC AMELOBLAST ASSOCIATED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MELANOMA CELL; MIGRATION INHIBITION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOSKELETON; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84877021352     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-227     Document Type: Article

References (72)

1. Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008, 128(12):2905-2908. 10.1038/jid.2008.159, 2741632, 18615112.
2. Bedrosian I, Faries MB, Guerry DT, Elenitsas R, Schuchter L, Mick R, Spitz FR, Bucky LP, Alavi A, Elder DE. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 2000, 7(4):262-267. 10.1007/s10434-000-0262-z, 10819365.
3. Haass NK, Smalley KS. Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther 2009, 13(5):283-296. 10.1007/BF03256334, 19791833.
4. Larson AR, Konat E, Alani RM. Melanoma biomarkers: current status and vision for the future. Nat Clin Pract Oncol 2009, 6(2):105-117. 10.1038/ncponc1296, 19107110.
5. Joyce CW, Murphy IG, Rafferty M, Ryan D, McDermott EW, Gallagher WM. Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. Expert Rev Proteomics 2012, 9(4):415-423. 10.1586/epr.12.5, 22967078.
6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353(20):2135-2147. 10.1056/NEJMoa050092, 16291983.
7. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004, 122(2):337-341. 10.1046/j.0022-202X.2004.22243.x, 2586668, 15009714.
8. Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012, 2012:354191. 3195305, 22013435.
9. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M. beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011, 20(6):741-754. 10.1016/j.ccr.2011.10.030, 3241928, 22172720.
10. Solomon A, Murphy CL, Weaver K, Weiss DT, Hrncic R, Eulitz M, Donnell RL, Sletten K, Westermark G, Westermark P. Calcifying epithelial odontogenic (Pindborg) tumor-associated amyloid consists of a novel human protein. J Lab Clin Med 2003, 142(5):348-355. 10.1016/S0022-2143(03)00149-5, 14647039.
11. Murphy CL, Kestler DP, Foster JS, Wang S, Macy SD, Kennel SJ, Carlson ER, Hudson J, Weiss DT, Solomon A. Odontogenic ameloblast-associated protein nature of the amyloid found in calcifying epithelial odontogenic tumors and unerupted tooth follicles. Amyloid 2008, 15(2):89-95. 10.1080/13506120802005965, 18484335.
12. Park JC, Park JT, Son HH, Kim HJ, Jeong MJ, Lee CS, Dey R, Cho MI. The amyloid protein APin is highly expressed during enamel mineralization and maturation in rat incisors. Eur J Oral Sci 2007, 115(2):153-160. 10.1111/j.1600-0722.2007.00435.x, 17451507.
13. Moffatt P, Smith CE, St-Arnaud R, Nanci A. Characterization of Apin, a secreted protein highly expressed in tooth-associated epithelia. J Cell Biochem 2008, 103(3):941-956. 10.1002/jcb.21465, 17647262.
14. Aung PP, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T, Bosserhoff AK, Yasui W. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 2006, 25(17):2546-2557. 10.1038/sj.onc.1209279, 16331256.
15. Kestler DP, Foster JS, Macy SD, Murphy CL, Weiss DT, Solomon A. Expression of odontogenic ameloblast-associated protein (ODAM) in dental and other epithelial neoplasms. Mol Med 2008, 14(5-6):318-326. 2323332, 18472969.
16. Lee HK, Park SJ, Oh HJ, Kim JW, Bae HS, Park JC. Expression pattern, subcellular localization, and functional implications of ODAM in ameloblasts, odontoblasts, osteoblasts, and various cancer cells. Gene Expr Patterns 2012, 12(3-4):102-108.
17. Siddiqui S, Bruker CT, Kestler DP, Foster JS, Gray KD, Solomon A, Bell JL. Odontogenic ameloblast associated protein as a novel biomarker for human breast cancer. Am Surg 2009, 75(9):769-775. discussion 775.
18. Kestler DP, Foster JS, Bruker CT, Prenshaw JW, Kennel SJ, Wall JS, Weiss DT, Solomon A. ODAM expression inhibits human breast cancer tumorigenesis. Breast Cancer (Auckl) 2011, 5:73-85.
19. Siddiqui S, Gandhi SS, Bruker CT, Gray KD, Bell JL, Kestler D, Lewis JM. Primary tumor staining with ODAM, a novel biomarker, is predictive for stage III melanoma. Ann Surg Oncol 2010, 17:S107-S108.
20. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor RE, Nakajima M, Hendrix MJ. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 1991, 47(2):227-237. 10.1002/ijc.2910470211, 1671030.
21. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 2001, 21(3):794-810. 10.1128/MCB.21.3.794-810.2001, 86671, 11154267.
22. Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 2003, 278(42):41355-41366. 10.1074/jbc.M302830200, 12904306.
23. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010, 8(5):629-642. 10.1158/1541-7786.MCR-10-0139, 20460404.
24. Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001, 276(36):33630-33637. 10.1074/jbc.M105322200, 11443134.
25. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7(8):606-619. 10.1038/nrg1879, 16847462.
26. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307(5712):1098-1101. 10.1126/science.1106148, 15718470.
27. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998, 273(22):13375-13378. 10.1074/jbc.273.22.13375, 9593664.
28. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95(1):29-39. 10.1016/S0092-8674(00)81780-8, 9778245.
29. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999, 96(11):6199-6204. 10.1073/pnas.96.11.6199, 26859, 10339565.
30. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999, 18(50):7034-7045. 10.1038/sj.onc.1203183, 10597304.
31. Nishio C, Wazen R, Kuroda S, Moffatt P, Nanci A. Disruption of periodontal integrity induces expression of apin by epithelial cell rests of Malassez. J Periodontal Res 2010, 45(6):709-713. 10.1111/j.1600-0765.2010.01288.x, 20572917.
32. Nishio C, Wazen R, Kuroda S, Moffatt P, Nanci A. Expression pattern of odontogenic ameloblast-associated and amelotin during formation and regeneration of the junctional epithelium. Eur Cell Mater 2010, 20:393-402.
33. Moffatt P, Smith CE, Sooknanan R, St-Arnaud R, Nanci A. Identification of secreted and membrane proteins in the rat incisor enamel organ using a signal-trap screening approach. Eur J Oral Sci 2006, 114(Suppl 1):139-146. discussion 164-135, 380-131.
34. Lee HK, Lee DS, Ryoo HM, Park JT, Park SJ, Bae HS, Cho MI, Park JC. The odontogenic ameloblast-associated protein (ODAM) cooperates with RUNX2 and modulates enamel mineralization via regulation of MMP-20. J Cell Biochem 2010, 111(3):755-767. 10.1002/jcb.22766, 20665536.
35. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947. 10.1126/science.275.5308.1943, 9072974.
36. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15(4):356-362. 10.1038/ng0497-356, 9090379.
37. Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco BI, Ho A, Wakeham A, Itie A, Khoo W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998, 8(21):1169-1178. 10.1016/S0960-9822(07)00488-5, 9799734.
38. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999, 96(4):1563-1568. 10.1073/pnas.96.4.1563, 15517, 9990064.
39. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501. 10.1038/nrc839, 12094235.
40. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000, 157(4):1123-1128. 10.1016/S0002-9440(10)64627-5, 1850161, 11021816.
41. Deichmann M, Thome M, Benner A, Egner U, Hartschuh W, Naher H. PTEN/MMAC1 expression in melanoma resection specimens. Br J Cancer 2002, 87(12):1431-1436. 10.1038/sj.bjc.6600653, 2376294, 12454773.
42. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002, 99(1):63-67. 10.1002/ijc.10294, 11948493.
43. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011, 11(4):289-301.
44. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009, 4:127-150. 10.1146/annurev.pathol.4.110807.092311, 2710138, 18767981.
45. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13(5):283-296.
46. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010, 42(5):454-458. 10.1038/ng.556, 3118559, 20400965.
47. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011, 476(7359):163-169. 10.1038/nature10275, 3206311, 21833082.
48. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. Regulation of PTEN transcription by p53. Mol Cell 2001, 8(2):317-325. 10.1016/S1097-2765(01)00323-9, 11545734.
49. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007, 128(1):129-139. 10.1016/j.cell.2006.11.039, 1828909, 17218260.
50. Van Themsche C, Leblanc V, Parent S, Asselin E. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J Biol Chem 2009, 284(31):20462-20466. 10.1074/jbc.C109.009522, 2742810, 19473982.
51. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15(4):304-314. 10.1016/j.ccr.2009.02.012, 2673492, 19345329.
52. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010, 18(5):423-435. 10.1016/j.ccr.2010.10.025, 3022383, 21075308.
53. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 2005, 280(42):35195-35202. 10.1074/jbc.M503045200, 16107342.
54. Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 2009, 325(5945):1261-1265. 10.1126/science.1173569, 2936784, 19729658.
55. Fata JE, Debnath S, Jenkins EC, Fournier MV. Nongenomic mechanisms of PTEN regulation. Int J Cell Biol 2012, 2012:379685. 3320059, 22536248.
56. Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 2002, 75(1):73-85. 10.1023/A:1016536725958, 12500936.
57. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005, 65(16):7370-7377. 10.1158/0008-5472.CAN-05-0807, 16103089.
58. Bhoopathi P, Gorantla B, Sailaja GS, Gondi CS, Gujrati M, Klopfenstein JD, Rao JS. SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT. PLoS One 2012, 7(5):e36093. 10.1371/journal.pone.0036093, 3342296, 22567126.
59. Kawasaki K, Buchanan AV, Weiss KM. Biomineralization in humans: making the hard choices in life. Annu Rev Genet 2009, 43:119-142. 10.1146/annurev-genet-102108-134242, 19659443.
60. Kawasaki K, Lafont AG, Sire JY. The evolution of milk casein genes from tooth genes before the origin of mammals. Mol Biol Evol 2011, 28(7):2053-2061. 10.1093/molbev/msr020, 21245413.
61. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002, 14(5):608-616. 10.1016/S0955-0674(02)00361-7, 12231357.
62. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil?. J Cell Biochem 2004, 92(4):679-690. 10.1002/jcb.20091, 15211566.
63. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 2008, 11(6):231-246. 10.1016/j.drup.2008.08.005, 18849185.
64. Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS, Lakka S. Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ 2010, 17(10):1529-1539. 10.1038/cdd.2010.28, 3025815, 20339379.
65. Cheng L, Sage EH, Yan Q. SPARC fusion protein induces cellular adhesive signaling. PLoS One 2013, 8(1):e53202. 10.1371/journal.pone.0053202, 3549909, 23349702.
66. Yan Q, Weaver M, Perdue N, Sage EH. Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells. J Cell Physiol 2005, 203(1):286-294. 10.1002/jcp.20226, 15534859.
67. Das T, Bae YH, Wells A, Roy P. Profilin-1 overexpression upregulates PTEN and suppresses AKT activation in breast cancer cells. J Cell Physiol 2009, 218(2):436-443. 10.1002/jcp.21618, 2874249, 18937284.
68. Zou L, Jaramillo M, Whaley D, Wells A, Panchapakesa V, Das T, Roy P. Profilin-1 is a negative regulator of mammary carcinoma aggressiveness. Br J Cancer 2007, 97(10):1361-1371. 10.1038/sj.bjc.6604038, 2360229, 17940506.
69. Zou L, Hazan R, Roy P. Profilin-1 overexpression restores adherens junctions in MDA-MB-231 breast cancer cells in R-cadherin-dependent manner. Cell Motil Cytoskeleton 2009, 66(12):1048-1056. 10.1002/cm.20407, 2783708, 19593789.
70. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012, 18(6):892-901. 10.1038/nm.2772, 22610277.
71. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15(14):4649-4664. 10.1158/1078-0432.CCR-09-0317, 19567590.
72. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008, 118(9):3051-3064. 2518074, 18725989.